NYSE - Nasdaq Real Time Price USD
Arcus Biosciences, Inc. (RCUS)
8.11
+0.02
+(0.25%)
At close: April 23 at 4:00:02 PM EDT
8.28
+0.17
+(2.10%)
After hours: April 23 at 6:54:50 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
258,000
258,000
117,000
112,000
383,000
Operating Expense
568,000
568,000
457,000
392,000
329,000
Operating Income
-310,000
-310,000
-340,000
-280,000
54,000
Net Non Operating Interest Income Expense
48,000
48,000
39,000
14,000
1,000
Other Income Expense
-20,000
-20,000
--
--
--
Pretax Income
-283,000
-283,000
-301,000
-266,000
55,000
Tax Provision
1,000
1,000
6,000
1,000
2,000
Net Income Common Stockholders
-283,000
-283,000
-307,000
-267,000
53,000
Diluted NI Available to Com Stockholders
-283,000
-283,000
-307,000
-267,000
53,000
Basic EPS
-3.19
-3.14
-4.15
-3.71
0.76
Diluted EPS
-3.19
-3.14
-4.15
-3.71
0.71
Basic Average Shares
86,000
90,100
74,000
72,000
69,345.49
Diluted Average Shares
86,000
90,100
74,000
72,000
73,966.27
Total Operating Income as Reported
-330,000
-330,000
-340,000
-280,000
54,000
Total Expenses
568,000
568,000
457,000
392,000
329,000
Net Income from Continuing & Discontinued Operation
-283,000
-283,000
-307,000
-267,000
53,000
Normalized Income
-267,200
-267,200
-307,000
-267,000
53,000
Interest Income
52,000
52,000
41,000
16,000
1,000
Interest Expense
4,000
4,000
2,000
2,000
--
Net Interest Income
48,000
48,000
39,000
14,000
1,000
EBIT
-279,000
-279,000
-299,000
-264,000
55,000
EBITDA
-269,000
-269,000
-291,000
-258,000
59,000
Reconciled Depreciation
10,000
10,000
8,000
6,000
4,000
Net Income from Continuing Operation Net Minority Interest
-283,000
-283,000
-307,000
-267,000
53,000
Total Unusual Items Excluding Goodwill
-20,000
-20,000
--
--
--
Total Unusual Items
-20,000
-20,000
--
--
--
Normalized EBITDA
-249,000
-249,000
-291,000
-258,000
59,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-4,200
-4,200
--
--
--
12/31/2021 - 3/15/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ZBIO Zenas BioPharma, Inc.
9.91
+1.07%
BCYC Bicycle Therapeutics plc
8.67
-0.69%
REPL Replimune Group, Inc.
8.83
+1.38%
MRUS Merus N.V.
41.83
-3.19%
IMCR Immunocore Holdings plc
29.80
+0.95%
ORIC ORIC Pharmaceuticals, Inc.
5.17
-0.96%
CGEM Cullinan Therapeutics, Inc.
8.38
+0.12%
JANX Janux Therapeutics, Inc.
31.62
+5.36%
IDYA IDEAYA Biosciences, Inc.
18.82
+1.02%
KURA Kura Oncology, Inc.
6.37
+0.95%